Wedbush Reaffirms Outperform Rating for iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a note issued to investors on Tuesday,RTT News reports. They currently have a $25.00 price target on the stock. Wedbush’s price objective indicates a potential upside of 183.13% from the company’s previous close.

Several other research firms have also commented on ITOS. Wells Fargo & Company started coverage on shares of iTeos Therapeutics in a research note on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price target on shares of iTeos Therapeutics in a report on Monday, September 16th. Finally, JPMorgan Chase & Co. reduced their price objective on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a research note on Monday, August 12th.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS opened at $8.83 on Tuesday. iTeos Therapeutics has a twelve month low of $8.41 and a twelve month high of $18.75. The firm has a 50-day moving average of $10.69 and a two-hundred day moving average of $14.06.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in iTeos Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company’s stock worth $20,468,000 after acquiring an additional 9,660 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of iTeos Therapeutics by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock worth $13,481,000 after purchasing an additional 117,159 shares during the period. Candriam S.C.A. purchased a new position in iTeos Therapeutics during the second quarter valued at approximately $7,558,000. Algert Global LLC increased its stake in iTeos Therapeutics by 92.0% in the 3rd quarter. Algert Global LLC now owns 256,139 shares of the company’s stock valued at $2,615,000 after buying an additional 122,730 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in iTeos Therapeutics in the 1st quarter worth approximately $3,337,000. Hedge funds and other institutional investors own 97.16% of the company’s stock.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.